AU2017338915B2 - TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof - Google Patents

TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof Download PDF

Info

Publication number
AU2017338915B2
AU2017338915B2 AU2017338915A AU2017338915A AU2017338915B2 AU 2017338915 B2 AU2017338915 B2 AU 2017338915B2 AU 2017338915 A AU2017338915 A AU 2017338915A AU 2017338915 A AU2017338915 A AU 2017338915A AU 2017338915 B2 AU2017338915 B2 AU 2017338915B2
Authority
AU
Australia
Prior art keywords
seq
fusion protein
type
amino acid
position corresponding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017338915A
Other languages
English (en)
Other versions
AU2017338915A1 (en
Inventor
Roselyne CASTONGUAY
Asya Grinberg
Ravindra Kumar
Dianne S. Sako
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acceleron Pharma Inc
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of AU2017338915A1 publication Critical patent/AU2017338915A1/en
Application granted granted Critical
Publication of AU2017338915B2 publication Critical patent/AU2017338915B2/en
Priority to AU2025200960A priority Critical patent/AU2025200960A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2017338915A 2016-10-05 2017-10-05 TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof Active AU2017338915B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025200960A AU2025200960A1 (en) 2016-10-05 2025-02-12 TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662404563P 2016-10-05 2016-10-05
US62/404,563 2016-10-05
PCT/US2017/055420 WO2018067873A2 (en) 2016-10-05 2017-10-05 Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025200960A Division AU2025200960A1 (en) 2016-10-05 2025-02-12 TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof

Publications (2)

Publication Number Publication Date
AU2017338915A1 AU2017338915A1 (en) 2019-04-18
AU2017338915B2 true AU2017338915B2 (en) 2024-11-21

Family

ID=61831499

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017338915A Active AU2017338915B2 (en) 2016-10-05 2017-10-05 TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof
AU2025200960A Pending AU2025200960A1 (en) 2016-10-05 2025-02-12 TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025200960A Pending AU2025200960A1 (en) 2016-10-05 2025-02-12 TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof

Country Status (6)

Country Link
US (3) US11440949B2 (enExample)
EP (1) EP3522912A4 (enExample)
JP (3) JP7097354B2 (enExample)
AU (2) AU2017338915B2 (enExample)
CA (1) CA3039545A1 (enExample)
WO (1) WO2018067873A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170306027A1 (en) 2016-04-06 2017-10-26 Acceleron Pharma Inc. Alk7 antagonists and uses thereof
AU2017338916B2 (en) 2016-10-05 2022-03-24 Acceleron Pharma Inc. Variant ActRIIB proteins and uses thereof
EP3788067A4 (en) 2018-05-03 2022-01-19 Acceleron Pharma Inc. NOVEL BINDERS OF TGFBETA SUPERFAMILY LIGANDS AND THEIR USES
AU2019262139A1 (en) * 2018-05-03 2020-11-26 Acceleron Pharma Inc. Multispecific binders of TGFβ-superfamily ligands and uses thereof
WO2020198293A1 (en) * 2019-03-25 2020-10-01 Northshore University Health System Methods and compositions comprising enhanced targeted immune gene therapy for the treatment of cancer
WO2021158695A1 (en) * 2020-02-03 2021-08-12 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
US20230183319A1 (en) * 2020-02-03 2023-06-15 Acceleron Pharma Inc. Variant actriib proteins and uses thereof
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
US20250002588A1 (en) 2023-04-07 2025-01-02 Diagonal Therapeutics Inc. Bispecific agonistic antibodies to activin a receptor like type 1 (alk1)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120149879A1 (en) * 2008-09-26 2012-06-14 Ulrich Brinkmann Bispecific anti-egfr/anti-igf-1r antibodies
WO2016164089A2 (en) * 2015-04-06 2016-10-13 Acceleron Pharma Inc. Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002510198A (ja) 1997-05-16 2002-04-02 ザ プロクター アンド ギャンブル カンパニー スクリーニングのための骨形態形成タンパク質（ｂｍｐ）受容体複合体の使用
US7521211B2 (en) * 2005-04-05 2009-04-21 Regeneron Pharmaceuticals, Inc IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof
WO2010031168A1 (en) 2008-09-17 2010-03-25 National Research Council Of Canada HETERO-MULTIVALENT BINDING AGENTS FOR MEMBERS OF THE TGFβ SUPERFAMILY
CN103429620B (zh) * 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
RU2678117C2 (ru) 2012-11-02 2019-01-23 Селджин Корпорейшн Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
CN114699529A (zh) * 2014-06-13 2022-07-05 阿塞勒隆制药公司 用于治疗溃疡的方法和组合物
CA2980757A1 (en) 2015-03-26 2016-09-29 Acceleron Pharma Inc. Follistatin-related fusion proteins and uses thereof
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
CN113683708A (zh) 2015-04-06 2021-11-23 阿塞勒隆制药公司 单臂i型和ii型受体融合蛋白和其用途
US20170306027A1 (en) 2016-04-06 2017-10-26 Acceleron Pharma Inc. Alk7 antagonists and uses thereof
CN110678195A (zh) 2016-10-05 2020-01-10 阿塞勒隆制药公司 ALK4:ActRIIB异多聚体及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120149879A1 (en) * 2008-09-26 2012-06-14 Ulrich Brinkmann Bispecific anti-egfr/anti-igf-1r antibodies
WO2016164089A2 (en) * 2015-04-06 2016-10-13 Acceleron Pharma Inc. Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof

Also Published As

Publication number Publication date
AU2017338915A1 (en) 2019-04-18
WO2018067873A2 (en) 2018-04-12
JP2022137108A (ja) 2022-09-21
AU2025200960A1 (en) 2025-03-06
US12421295B2 (en) 2025-09-23
EP3522912A2 (en) 2019-08-14
JP7504947B2 (ja) 2024-06-24
CA3039545A1 (en) 2018-04-12
JP7097354B2 (ja) 2022-07-07
US11440949B2 (en) 2022-09-13
JP2024113195A (ja) 2024-08-21
JP2019536439A (ja) 2019-12-19
EP3522912A4 (en) 2020-10-14
US20250368720A1 (en) 2025-12-04
WO2018067873A3 (en) 2018-05-17
US20210147508A1 (en) 2021-05-20
US20230265161A1 (en) 2023-08-24

Similar Documents

Publication Publication Date Title
US20240158468A1 (en) Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof
US12338273B2 (en) Single-arm type I and type II receptor fusion proteins and uses thereof
US12240887B2 (en) Variant ActRIIB proteins and uses thereof
US12421295B2 (en) TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)